5D8J
Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | DIAMOND BEAMLINE I02 |
Synchrotron site | Diamond |
Beamline | I02 |
Temperature [K] | 80 |
Detector technology | PIXEL |
Collection date | 2013-05-29 |
Detector | DECTRIS PILATUS 6M-F |
Wavelength(s) | 0.97949 |
Spacegroup name | P 1 21 1 |
Unit cell lengths | 71.499, 66.040, 75.678 |
Unit cell angles | 90.00, 111.67, 90.00 |
Refinement procedure
Resolution | 33.020 - 3.000 |
R-factor | 0.20821 |
Rwork | 0.205 |
R-free | 0.26922 |
Structure solution method | MOLECULAR REPLACEMENT |
RMSD bond length | 0.013 |
RMSD bond angle | 1.729 |
Data reduction software | xia2 |
Data scaling software | SCALA |
Phasing software | PHASER |
Refinement software | REFMAC (5.8.0131) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 33.030 | 2.370 |
High resolution limit [Å] | 2.230 | 2.230 |
Rmerge | 0.011 | 0.352 |
Number of reflections | 13077 | |
<I/σ(I)> | 6.8 | 1.7 |
Completeness [%] | 98.6 | 98.4 |
Redundancy | 2.6 | 2.6 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 5.5 | 296 | 100mM 2-(N-morpholino)ethanesulfonic acid, 150mM ammonium sulfate, 24% PEG 4000 |